Uterine fibroids and current clinical challenges

The role of TWIST, SERPINB5, and SERPIN1 genes in uterine leiomyomas

OBJECTIVE

The aim of this study is investigate the role of the Twist homolog 1 (TWIST), serine peptidase inhibitor (SERPINB5), and plasminogen activator inhibitor 1 (SERPIN1) genes in uterine leiomyoma etiopathogenesis.

MATERIAL AND METHODS

Twelve patients, aged between 39 and 58, and had a hysterectomy, were included in the study. The size of the leiomyomas was between 20 and 130 mm based on gross pathology after hysterectomy. Tissue samples were obtained from normal myometrium and leiomyoma (1 cm(3)) tissue of the uterus of the patients and stored at -86°C. Samples were divided to two groups after histopathological evaluation of the uterus: normal myometrial tissues as control group (Group 1) and leiomyoma tissue as the study group (Group 2). The TWIST, SERPINB5, and SERPIN1 genes were studied for uterine leiomyoma etiopathogenesis.

RESULTS

TWIST gene expression was significantly higher in the uterine leiomyoma tissue (p<0.001). SERPINB5 and SERPIN1 gene expression was decreased in the uterine leiomyoma tissue, but the differences were not statistically significant.

CONCLUSION

TWIST gene activity is significantly increased in leiomyoma tissue when compared to normal myometrium. In spite of the fact that the development of uterine leiomyomas is estrogen- and progesterone-dependent, myometrial cells could be triggered by the TWIST gene for uterine leiomyoma development.

Uterine fibroids: current perspectives

Uterine fibroids are a major cause of morbidity in women of a reproductive age (and sometimes even after menopause). There are several factors that are attributed to underlie the development and incidence of these common tumors, but this further corroborates their relatively unknown etiology. The most likely presentation of fibroids is by their effect on the woman's menstrual cycle or pelvic pressure symptoms. Leiomyosarcoma is a very rare entity that should be suspected in postmenopausal women with fibroid growth (and no concurrent hormone replacement therapy). The gold standard diagnostic modality for uterine fibroids appears to be gray-scale ultrasonography, with magnetic resonance imaging being a close second option in complex clinical circumstances. The management of uterine fibroids can be approached medically, surgically, and even by minimal access techniques. The recent introduction of selective progesterone receptor modulators (SPRMs) and aromatase inhibitors has added more armamentarium to the medical options of treatment. Uterine artery embolization (UAE) has now been well-recognized as a uterine-sparing (fertility-preserving) method of treating fibroids. More recently, the introduction of ultrasound waves (MRgFUS) or radiofrequency (VizAblate™ and Acessa™) for uterine fibroid ablation has added to the options of minimal access treatment. More definite surgery in the form of myomectomy or hysterectomy can be performed via the minimal access or open route methods. Our article seeks to review the already established information on uterine fibroids with added emphasis on contemporary knowledge.